Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Tyra has built a nimble and experienced team to rapidly translate new discoveries into the clinic with a singular focus on acquired resistance in oncology.
Tyra Biosciences was founded in 2018 by Todd Harris alongside with Daniel C Bensen. The company is headquartered in Carlsbad, California.
Tyra Biosciences is combining insights from structure-based drug design (SBDD), kinase biology, computational chemistry and smart clinical development to discover and develop next-gen small molecule therapies that are active against both wild type and mutant targets.
Tyra Biosciences has raised $50M in a Series A financing on Jan 10, 2020. The financing round was co-led by Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group, and Canaan.